StockWatch
·
WOCKHARDT LTD. · Q2 FY-2027 · PREVIEW

Turnaround Holds — Profitability Momentum into Q2 on Watch

After Q1 FY27 delivered 26% revenue growth and a return to ₹107 Cr profit, Wockhardt faces the proof test: can the turnaround sustain? Analysts expect continued recovery at ₹2,175 target, but a ₹15 Cr customs penalty and margin pressures warrant watching on result day.

Q2 FY27 resultsWOCKPHARMAWOCKHARDT LTD.29 Oct 2026 · 3 min read

The Setup: Turnaround Traction into Q2

Wockhardt enters Q2 FY27 off a strong Q1 — revenue up 26% YoY to ₹929 Cr, with PAT swinging from a ₹108 Cr loss to a ₹107 Cr profit. The Street expects the recovery to hold. Analyst consensus targets sit at ₹2,175 on the back of sustained PAT growth through FY27 as the real valuation driver. The stock trades at ₹1,913.4 as of Oct 28, down 21% from ATH of ₹2,422.3 — inviting debate on whether the recovery is real or a head-fake worth a re-entry.

Revenue expectation

~₹950–980 Cr

Assuming sequential+YoY momentum from Q1's 26% growth trajectory (on-plan)

Profit after tax

~₹110–130 Cr

Sustained double-digit return to profitability; margin hold at 22%+ critical

EBITDA margin

~22–24%

Q1 delivered 23.6% (₹219 Cr EBITDA on ₹929 Cr revenue). Watch for input cost/FX pressures

A strong Q2 print would show revenue in the ₹950–1,000 Cr band and PAT ₹110 Cr+, with EBITDA margin staying 22%+—confirming the turnaround is run-rate, not a blip. A weak print would be revenue below ₹920 Cr or PAT below ₹100 Cr—signalling momentum loss or margin headwinds despite top-line recovery. Watch for management commentary on API demand (especially post-customs scrutiny), any supply-chain pressure, and competitive pricing in key segments.

On Track for FY27 Guidance?

Wockhardt has not issued explicit full-year guidance, but the turnaround narrative is clear: divestiture of underperforming US generic assets and pivot to innovation-led, higher-margin segments are working. Q1 proved the business can grow top-line at 26% and hit mid-20s EBITDA margins while returning to profit. Q2 will test whether this is a new run-rate or a one-off bump. If management confirms or guides for low-to-mid-₹400 Cr PAT for FY27 (₹100+ per quarter), that validates the turnaround and the ₹2,000+ target. If they lower expectations or flag margin pressure, expect profit-taking.

Since Last Quarter: Filings Scan

Aug 25, 2026: Customs penalty adjudication—Commissioner of Customs, Nhava Sheva-II, imposed ₹5 Cr penalty + ₹10 Cr redemption fine under Sections 114(iii) and 125(1) of the Customs Act for alleged API misclassification. Company states no material impact on financials/operations and plans to challenge the order in appellate process. No production disruption signalled. Aug 10, 2026: QIP monitoring report—CRISIL confirmed no deviation in utilization of proceeds from the earlier QIP; capital deployment on-track. Aug 10, 2026: Antibiotic Academy—Company launched Wockhardt Antibiotic Academy, a CSR/patient-dialogue initiative on antimicrobial resistance; strategic/CSR, not financial. Routine: AGM held Aug 10; board approved Q1 results same day; trading window closure (Oct 1 to 48h post-announcement) standard for result season.

Three Things to Watch on November 2

When Wockhardt announces Q2 FY27 results at 10:30 IST on Saturday, Nov 2, focus on:
  • 1 · Revenue and growth rate

    Is it ₹950–980 Cr (validating continued 20%+ growth)? Or does it drop to ₹900–920 Cr (suggesting market softness or margin-sacrifice pricing)? This is the headline growth number that validates the turnaround narrative.

  • 2 · PAT and EBITDA margin

    Expected ₹110–130 Cr PAT. If it lands here with EBITDA margin 22%+, the turnaround holds and ₹2,000+ is in play. If PAT < ₹100 Cr despite revenue growth, listen closely for margin-compression commentary—pricing pressure, input costs, or competitive intensity.

  • 3 · FY27 PAT outlook and customs penalty clarity

    Management will need to quantify the ₹15 Cr penalty impact on cash/working capital and provide an appeal timeline. Any FY27 PAT guidance (or revision) will move the needle. Also watch for API-demand color post-FDA/customs scrutiny and capex intensity for innovation assets.

Wockhardt's turnaround story got a real Q1 test and passed: 26% revenue growth, return to ₹107 Cr profit, and 23.6% EBITDA margin. Q2 will answer whether that's a durable new floor or a ceiling. Analysts are cautiously constructive at ₹2,175 target, betting FY27 delivers ₹400+ Cr PAT. The ₹15 Cr customs penalty is friction but not a deal-breaker if the company confirms zero operational impact and a clear appeal path. On Nov 2, watch for three things: revenue holding 20%+ growth, PAT above ₹110 Cr, and management's FY27 PAT confidence. A beat on all three could re-rate the stock toward ₹2,200+; a miss on revenue or margins will trigger a rethink of the turnaround thesis.

Informational and educational content only. Not investment advice.